Warner Chilcott (WCRX)

20.61 +1.01  +5.15%  May 21, 8:00PM
Add to Watchlists Create an Alert

Warner Chilcott R&D Expense Quarterly:

30.00M for Dec. 31, 2012
View Full Chart

Warner Chilcott R&D Expense Quarterly Chart

    Warner Chilcott Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 30.00M
    Sept. 30, 2012 25.00M
    June 30, 2012 23.00M
    March 31, 2012 25.00M
    Dec. 31, 2011 26.00M
    Sept. 30, 2011 26.00M
    June 30, 2011 25.00M
    March 31, 2011 31.00M
    Dec. 31, 2010 30.84M
    Sept. 30, 2010 33.26M
    June 30, 2010 51.26M
    March 31, 2010 31.15M
    Dec. 31, 2009 29.29M
    Sept. 30, 2009 11.63M
    June 30, 2009 11.94M
       
    March 31, 2009 23.87M
    Dec. 31, 2008 15.23M
    Sept. 30, 2008 9.997M
    June 30, 2008 12.55M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    WCRX R&D Expense Quarterly Benchmarks

    Companies
    Mylan 126.49M
    Actavis 132.10M
    Valeant Pharmaceuticals International 23.80M

    WCRX R&D Expense Quarterly Rankings

    Overall 96th percentile
    294 of 8002
    Sector 89th percentile
    74 of 684 in Healthcare
    Industry 82nd percentile
    12 of 68 in Drug Manufacturers - Specialty & Generic

    WCRX R&D Expense Quarterly Range, Past 5 Years

    Minimum 9.997M Sep 2008
    Maximum 51.26M Jun 2010
    Average 24.84M